A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS (RCTS) OF EGFR-TARGETED MONOCLONAL ANTIBODY (MAB) THERAPY IN ADVANCED COLORECTAL CANCER (ACRC): IMPACT OF K-RAS STATUS

Documenti analoghi

• Impact of K-ras status on the effects of EGFR-targeted monoclonal antibody (MAb) therapy in advanced colorectal cancer (ACRC): A systematic review and meta-analysis of randomized controlled trials (RCTs)
  di: Vale, C, et al.
  Pubblicazione: (2009)
• THROMBOCYTOSIS AS A PREDICTIVE AND PROGNOSTIC MARKER IN ADVANCED COLORECTAL CANCER (ACRC): RESULTS OF THE MRC COIN TRIAL EXPLORED
  di: Maughan, T, et al.
  Pubblicazione: (2010)
• Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN)
  di: Maughan, T, et al.
  Pubblicazione: (2009)
• Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis.
  di: Vale, C, et al.
  Pubblicazione: (2012)
• Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis
  di: Vale, C, et al.
  Pubblicazione: (2012)